Ethical Simulation
After taking part in the ethics game, a couple of issues were presented which needed to be addressed in me taking part as a Quality Control Manager in the G-Bio Sport Company. Decision making steps were used differently for each issue to have the ability to address the issue in the correct fashion. I used two different ethical perspectives, and two different ethical lenses to make my decisions in this simulation. Even using these perspectives, and lenses my management decisions were not affected or influenced throughout the simulation. This simulation does bring up valid insights in how issues come up in my business. The first of the ethical issues presented in the simulation was a product shipped out to the consumer market by G-Bio Sport was tainted with an elevated amount of GBS-Fibranafren. During the most recent QA testing 100% of the products shipped to consumer markets contains an elevated amount of GBS-Fibranafren. The amounts are far beneath the FDA regulations, but exceed the levels we have permitted internally. The risks to consumers being affected by the product are low, but consumers with compromised immune systems could have a slightly higher risk of reactions with continued use of the product. I know based off of the lab results that 100% of the batch shipped to the consumer market is tainted with GBS-Fibranafren. In the second scenario the issue was to decide whether to sell a product that does not meet U.S. safety requirements in a foreign market that has lower safety restrictions. Through the FDA changing their regulations on the levels of GBS allowed in products G-Bio Sport was faced with distributing their products to foreign countries or disposing of them. The regulations in other countries differ from the FDA regulations, so if the product were to go into another country G-Bio Sport is still in the proper guidelines for